We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$45.1M
1-Year Est. Return
74.25%
This Fund
S&P 500
This Quarter
Est. Return
+34.63%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$208M
AUM Growth
-$246M
(-54%)
Cap. Flow
-$176M
Cap. Flow
% of AUM
-84.46%
Top 10 Holdings %
Top 10 Hldgs %
83.47%
Holding
151
New
27
Increased
12
Reduced
37
Closed
67
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HMTV
Hemisphere Media Group, Inc.
HMTV
|
+$9.46M |
| 2 |
Loop Industries
LOOP
|
+$2.38M |
| 3 |
TRNX
Taronis Technologies, Inc. Common Stock
TRNX
|
+$1.52M |
| 4 |
Novavax
NVAX
|
+$1.36M |
| 5 |
CODX
Co-Diagnostics
CODX
|
+$928K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$37.5M |
| 2 |
ESPR
Esperion Therapeutics
ESPR
|
+$6.39M |
| 3 |
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
|
+$4.97M |
| 4 |
State Street SPDR S&P Biotech ETF
XBI
|
+$4.47M |
| 5 |
Xeris Biopharma Holdings
XERS
|
+$3.45M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 10.57% |
| 2 | Materials | 0.95% |
| 3 | Consumer Discretionary | 0.9% |
| 4 | Technology | 0.61% |
| 5 | Industrials | 0.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CYTR
26
DELISTED
CytRx Corp
CYTR
| $629K | 0.3% |
974,945
-880,934
| -47% | -$554K |
|
27
XTI Aerospace
XTIA
$57.3M
| – | – |
0
| – | – |
|
|
OPGN
28
DELISTED
OpGen, Inc
OPGN
| $562K | 0.27% |
232
+169
| +268% | +$921K |
|
29
AquaBounty Technologies
AQB
$4.74M
| $561K | 0.27% |
12,802
-3,031
| -19% | -$148K |
|
|
NTBL
30
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
| $498K | 0.24% |
9,357
-58,449
| -86% | -$2.86M |
|
|
31
Novavax
NVAX
$1.21B
| $474K | 0.23% |
+43,000
| New | +$1.36M |
|
|
32
PUT
Novavax
NVAX
$1.21B
| $474K | 0.23% |
+430
| New | +$13.6K |
|
33
Perspective Therapeutics
CATX
$327M
| $467K | 0.22% |
127,968
-97,515
| -43% | -$381K |
|
34
Theriva Biologics
TOVX
$9.8M
| $465K | 0.22% |
2,740
-1,730
| -39% | -$287K |
|
|
TRNX
35
DELISTED
Taronis Technologies, Inc. Common Stock
TRNX
| $459K | 0.22% |
+144,320
| New | +$1.52M |
|
|
MDGSW
36
DELISTED
Medigus Ltd. Series C Warrant
MDGSW
| $457K | 0.22% |
1,014,587
-29,177
| -3% | -$17.1K |
|
37
PUT
MannKind Corp
MNKD
$1.21B
| $398K | 0.19% |
2,018
-370
| -15% | -$586 |
|
|
HYPD
38
Hyperion DeFi Inc
HYPD
$36.7M
| $392K | 0.19% |
819
-1,395
| -63% | -$487K |
|
|
SCON
39
DELISTED
Superconductor Technologies Inc.
SCON
| $392K | 0.19% |
26,147
-6,482
| -20% | -$98.9K |
|
40
vTv Therapeutics
VTVT
$122M
| $382K | 0.18% |
+5,579
| New | +$541K |
|
|
VXRT
41
DELISTED
Vaxart
VXRT
| $382K | 0.18% |
+197,001
| New | +$375K |
|
42
PUT
Altimmune
ALT
$581M
| $368K | 0.18% |
1,269
+596
| +89% | +$1.78K |
|
|
NURO
43
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
| $338K | 0.16% |
3,844
-4,458
| -54% | -$370K |
|
44
Oragenics
OGEN
$2.24M
| $299K | 0.14% |
+284
| New | +$447K |
|
45
CALL
Viking Therapeutics
VKTX
$3.93B
| $244K | 0.12% |
245
+145
| +145% | +$1.21K |
|
|
HURA
46
TuHURA Biosciences
HURA
$136M
| $243K | 0.12% |
28
-53
| -65% | -$360K |
|
47
Ocugen
OCGN
$420M
| $220K | 0.11% |
+31,668
| New | +$270K |
|
|
QNRX
48
Quoin Pharmaceuticals
QNRX
$8.44M
| $214K | 0.1% |
+2
| New | +$359K |
|
49
CALL
Karyopharm Therapeutics
KPTI
$161M
| $210K | 0.1% |
+24
| New | +$2.66K |
|
|
BLPH
50
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
| $202K | 0.1% |
+20,594
| New | +$227K |
|
Similar funds
CG
OC
ICCON
PCM
CAS
CM
MCMC
CTC
Sabby Management's Q1 2019 Portfolio in Review
As of Q1 2019, Sabby Management held 151 positions worth $208M, down 54% from $455M the previous quarter. Its ten largest holdings account for 83% of the portfolio.
Sabby Management withdrew a net $176M in Q1 2019, closing 67 positions and reducing 37 holdings. Its most notable exit was Esperion Therapeutics, an estimated $6.39M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 11% of assets, down from 21% a quarter earlier, followed by Materials and Consumer Discretionary.
Against the trend, Sabby Management opened a new position in Hemisphere Media Group, Inc. worth $113K.
- Sabby Management's largest Q1 2019 buy was Hemisphere Media Group, Inc.: 708,417 shares worth $113K.
- Sabby Management added most to OpGen, Inc in Q1 2019, an estimated $921K increase.
- Sabby Management's biggest Q1 2019 reduction was Biogen, cutting an estimated $37.5M.
- Sabby Management fully exited Esperion Therapeutics in Q1 2019, selling an estimated $6.39M.
- Sabby Management's ten largest holdings make up 83% of its $208M portfolio in Q1 2019.
- Sabby Management opened 27 new positions and closed 67 in Q1 2019.
- Sabby Management's portfolio value fell 54% quarter-over-quarter to $208M.
Based on Sabby Management's 13F filing for Q1 2019, filed 15 May 2019.